(Q40244548)

English

Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor

scientific article published on 4 August 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

based on heuristic

inferred from title

phosphorylation

1 reference

based on heuristic

inferred from title

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

Jochen A. Werner

8

object named as

Jochen A Werner

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Robert Mandic

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Chantal J Rodgarkia-Dara

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Li Zhu

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Benedikt J Folz

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Michael Bette

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Eberhard Weihe

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Andreas Neubauer

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

4 August 2006

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

580

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

4793-4800

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Epidemiology of head and neck cancer: magnitude of the problem

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Mechanisms controlling EGF receptor endocytosis and degradation

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Advances in molecular diagnostics and therapeutics in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53.

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.07.064

21 January 2018

Identifiers

10.1016/J.FEBSLET.2006.07.064

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40244548&oldid=1890721253"